Michel Dahan, SVP, Chief Business Officer at Akebia Therapeutics, Inc. (AKBA), sold 1,398 shares at $19.64 ($27K) on 2017-10-02, disclosed to the SEC on 2017-10-04.
Scheduled sale ($27k) by SVP, Chief Business Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| AKBA | SELL | 2024-02-29 | $16K | — | Filing → |
| AKBA | SELL | 2023-05-25 | $233K | — | Filing → |
| AKBA | SELL | 2023-03-03 | $18K | — | Filing → |